Dr. Barry Dworkin

Wegovy (semaglutide) now approved by Health Canada to reduce the risk of non-fatal heart attack in people with known cardiovascular disease in addition to its use for weight loss management.

Medical Mythbusting Commentary for November 28, 2024

Source:
Wegovy is a weight-loss drug. Health Canada says it can now be used to curb heart-attack risk

Related posts:

  1. Treatments for weight loss do exist, work well for many, and reveal our growing understanding of how our homeostatic, motivational, and executive brain centers interact with respect to weight control.
  2. Obesity drug Wegovy cut risk of serious heart problems by 20 per cent, study finds
  3. Cuts in salt would reduce stroke, heart risks: study
  4. Medications seem to work as well as stents for people with stable heart disease